Bill & Melinda Gates Foundation Announces $800k Pathogen Genomics Funding Call

Securing non-dilutive research and development grant funding is essential for African laboratories, reference centers, and universities striving to democratize genomic surveillance. The Gates Pathogen Sequencing Grants opportunity offers significant financial backing to pioneer affordable, operationally simple Next-Generation Sequencing (NGS) workflows across low- and middle-income country (LMIC) public health networks.

Gates Pathogen Sequencing Grants Call Overview

Grand Challenges: Innovations for Low-Cost and Simplified Pathogen Sequencing Workflows

• Funding Bodies: Bill & Melinda Gates Foundation, Temasek Foundation, managed by the United Nations Foundation.

• Target Applicants: Research institutes, academic institutions, national reference laboratories, non-profit organizations, for-profit entities, and government agencies. Multi-partner consortia led by LMIC investigators are strongly encouraged.

• Grant Scope: Funding under the Gates Pathogen Sequencing Grants targets amplicon-based or targeted sequencing strategies utilizing existing, widely deployed sequencing platforms (Illumina, Oxford Nanopore, MGI/BGI). The explicit objective is to lower end-to-end sample-to-sequence costs down to $1 to $10 USD per sample. In-scope targets include viral genomes (measles, polio, mpox, arboviruses), malaria drug/diagnostic resistance markers, TB drug resistance profiling, and bacterial AMR.

• Eligibility & In-Scope Criteria:

  • Open globally to institutional entities; individuals, sanctioned entities, and weapons/tobacco-related organizations are excluded.

  • Proposals for the Gates Pathogen Sequencing Grants must feature a clear technical roadmap capable of functioning in laboratories with limited automation, variable supply chains, and standard molecular biology staff.

  • Out of scope: Hardware/sequencing instrument development, incremental workflow tweaks, volume-discount savings, non-sequencing assays, or applicants unwilling to abide by open data and global access guidelines.

• Grant Tiers & Funding Amounts:

  • Tier 1 (Feasibility & Prototyping): Up to $300,000 USD over 24 months (early-stage proof-of-concept).

  • Tier 2 (Integrated Workflow Development): Up to $600,000 USD over 24 months (advancing functional prototypes).

  • Tier 3 (Validation in LMIC Public Health Settings): Up to $800,000 USD over 36 months (field validation in routine surveillance settings).

• Deadline: Tuesday, 29 September 2026 at 11:30 AM PDT (Closing in 25 days).

• How to Apply:

  • Submit proposals online via the official Grand Challenges Challenge Page.

  • Application Tip: Ensure your requested tier matches your existing preliminary data. Include a line-item preliminary cost model demonstrating how assay/reagent chemistry redesign achieves the $1–$10 per sample threshold without relying on bulk procurement discounts. Highlight your team’s real-world LMIC laboratory context as an operational advantage.

Strategic Research Insights and Gates Pathogen Sequencing Grants Impact

Genomic surveillance has become the cornerstone of international pathogen tracking and outbreak detection. African researchers who leverage the Gates Pathogen Sequencing Grants to design and validate sequencing workflows under local resource constraints will not only make routine surveillance financially viable across regional public health institutes but will also position their laboratories as critical nodes in global health security networks.

Frequently Asked Questions

Is this grant intended to fund the development of new sequencing machines? No. The Gates Pathogen Sequencing Grants call specifically excludes new hardware development. Proposals must utilize established, commercially available sequencing platforms (such as Illumina, Oxford Nanopore, or MGI/BGI) already present in LMIC reference laboratories.

What is the required per-sample target cost under the Gates Pathogen Sequencing Grants? Proposals submitted to the Gates Pathogen Sequencing Grants must demonstrate a credible technical pathway to achieve an end-to-end sample-to-sequence cost of $1 to $10 USD per sample through protocol, assay, or library preparation innovations.